Regulatory FDA Approves First Non-Antipsychotic Drug to Treat Agitation Associated with Dementia FDAThe U.S.NeuroscienceRead full story pharminent April 30, 2026 (Last updated: May 1, 2026) FDA The U.S. Neuroscience Read full story Post navigation Previous: Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)Next: Two biotechs raise a combined $556M in latest spurt of IPOs Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026